Date: 2014-10-30
Type of information: Nomination
Compound: director
Company: Vect-Horus (France)
Therapeutic area: Technology - Services
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 30, 2014, Vect-Horus, a biotechnology company that designs and develops peptide vectors facilitating the delivery of drugs or imaging agents, notably in the brain, announced the appointment of Dr. Jamal Temsamani as Director in charge of Drug Development & Corporate. He will lead the Company’s drug development programs from discovery to early clinical and will be in charge of industrial partnerships. Dr. Jamal Temsamani is also a member of the Management Committee of Vect-Horus.
Dr. Temsamani obtained his Ph.D. in molecular biology from the University of Montpellier. After completing a post-doctoral fellowship at the Worcester Foundation For Experimental Biology (MA, USA), he joined IDERA Pharmaceuticals (MA, USA), where he served as Associate-Director and then as Director of the Discovery group. Then, he held several positions, including as Vice President of R&D at Synt:em (Nimes) and CLL Pharma (Nice). He has a strong scientific expertise in the field of pharmacology and preclinical development.
Financial terms:
Latest news:
Is general: Yes
